FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers

Jul 20, 2020, 08:08 PM

In our exclusive interview, Dr. Drilon provided background on use of targeted therapy in advanced NSCLC, discussed the frequency of RET alterations, and expanded on the data from the LIBRETTO-001 trial that led to the accelerated approval of selpercatinib.